Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Cancer Research Society Doctoral Research Awards - CBCI

University of Toronto

$35,000.00

Exogenous hormone use and breast cancer risk among women with a pathogenic variant in the BRCA1 or BRCA2 gene

FY 2026-27

Summary
Exogenous hormone use is associated with an increased risk of breast cancer among the general population, but very few studies have been conducted among BRCA carriers. The aim of this study is to determine the association between exogenous hormone use (i.e., Contraceptives and menopausal hormone therapy) and breast cancer risk among women with a BRCA1 or BRCA2 mutation, by method, hormonal formulation, and duration. This is a prospective analysis of BRCA carriers enrolled in a longitudinal study with detailed data collection on various exposures, screening practices, and health outcomes at baseline and every two years thereafter. Given the early age of exposure, it is important to provide guidelines that reflect modern methods by BRCA gene.
Program
Cancer Research Society Doctoral Research Awards - CBCI
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
580350
Name
Rajkumar Anita
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Exogenous hormone use and breast cancer risk among women with a pathogenic variant in the BRCA1 or BRCA2 gene
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Toronto
Cihramount2
$35,000
Cihrequipment2
$0
Programname2
Cancer Research Society Doctoral Research Awards - CBCI
Keyworddelim
Cancer
Abstract
Exogenous hormone use is associated with an increased risk of breast cancer among the general population, but very few studies have been conducted among BRCA carriers. The aim of this study is to determine the association between exogenous hormone use (i.e., Contraceptives and menopausal hormone therapy) and breast cancer risk among women with a BRCA1 or BRCA2 mutation, by method, hormonal formulation, and duration. This is a prospective analysis of BRCA carriers enrolled in a longitudinal study with detailed data collection on various exposures, screening practices, and health outcomes at baseline and every two years thereafter. Given the early age of exposure, it is important to provide guidelines that reflect modern methods by BRCA gene.
Competitiondate
202604
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Rajkumar, Anita
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $35,000~ $0~